drugset
drugset / Trial / NCT04527250

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

NCT04527250 ↗

Phase 1 Completed 60 enrolled Ascletis Pharmaceuticals Co., Ltd. Hunan Provincial People's Hospital · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.

Timeline

Start
2020-09-16
Primary completion
2020-12-18
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ASC41 Unknown 1 mg Oral
Subject ASC41 Unknown 2 mg Oral
Subject ASC41 Unknown 5 mg Oral
Subject ASC41 Unknown 10 mg Oral
Subject ASC41 Unknown 20 mg Oral

Indications

No indication recorded.